Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia

Hagop M. Kantarjian*, Yun Su, Elias J. Jabbour, Helen Bhattacharyya, Eric Yan, Joseph C. Cappelleri, David I. Marks

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

28 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences